Parallel FISH and immunohistochemical studies of ALK status in 3244 non-small-cell lung cancers reveal major discordances.
about
ALK evaluation in the world of multiplex testing: Network Genomic Medicine (NGM): the Cologne model for implementing personalised oncologyPrecision medicine in NSCLC and pathology: how does ALK fit in the pathway?Tackling ALK in non-small cell lung cancer: the role of novel inhibitorsConcomitant EML4-ALK rearrangement and EGFR mutation in non small cell lung cancer patients: A literature review of 100 cases.A consensus statement on the gender perspective in lung cancer.Accurate identification of ALK positive lung carcinoma patients: novel FDA-cleared automated fluorescence in situ hybridization scanning system and ultrasensitive immunohistochemistryThe relevance of external quality assessment for molecular testing for ALK positive non-small cell lung cancer: results from two pilot rounds show room for optimization.Prevalence and natural history of ALK positive non-small-cell lung cancer and the clinical impact of targeted therapy with ALK inhibitorsMicro-cost Analysis of ALK Rearrangement Testing by FISH to Determine Eligibility for Crizotinib Therapy in NSCLC: Implications for Cost Effectiveness of Testing and TreatmentDetection of EML4-ALK in lung adenocarcinoma using pleural effusion with FISH, IHC, and RT-PCR methods.Inconsistent results in the analysis of ALK rearrangements in non-small cell lung cancerEconomic Analysis of Alternative Strategies for Detection of ALK Rearrangements in Non Small Cell Lung Cancer.Fluorescence in situ hybridization analysis of the ALK gene in 2,045 non-small cell lung cancer patients from North-Western Spain (Galicia).Sensitive and affordable diagnostic assay for the quantitative detection of anaplastic lymphoma kinase (ALK) alterations in patients with non-small cell lung cancer.Next-generation sequencing facilitates detection of the classic E13-A20 EML4-ALK fusion in an ALK-FISH/IHC inconclusive biopsy of a stage IV lung cancer patient: a case report.Responses to crizotinib in patients with ALK-positive lung adenocarcinoma who tested immunohistochemistry (IHC)-positive and fluorescence in situ hybridization (FISH)-negative.ALK FISH patterns and the detection of ALK fusions by next generation sequencing in lung adenocarcinoma.Diagnostic challenges in non-small-cell lung cancer: an integrated medicine approach.Quantification of Anaplastic Lymphoma Kinase Protein Expression in Non-Small Cell Lung Cancer Tissues from Patients Treated with CrizotinibThe Current Landscape of Anaplastic Lymphoma Kinase (ALK) in Non-Small Cell Lung Cancer: Emerging Treatment Paradigms and Future Directions.Current and developing therapies for the treatment of non-small cell lung cancer with ALK abnormalities: update and perspectives for clinical practice.ALK alterations and inhibition in lung cancer.Lung Cancer Biomarkers.Lung cancer as a paradigm for precision oncology in solid tumours.ALK in Non-Small Cell Lung Cancer (NSCLC) Pathobiology, Epidemiology, Detection from Tumor Tissue and Algorithm Diagnosis in a Daily Practice.ALK+ lung adenocarcinoma in never smokers and long-term ex-smokers: prevalence and detection by immunohistochemistry and fluorescence in situ hybridization.Responses to crizotinib and chemotherapy in patients with lung adenocarcinoma harboring a concomitant EGFR mutation and ALK gene rearrangement: A case report and review of the literature.High performance of targeted next generation sequencing on variance detection in clinical tumor specimens in comparison with current conventional methods.An Anaplastic Lymphoma Kinase Immunohistochemistry-Negative but Fluorescence In Situ Hybridization-Positive Lung Adenocarcinoma Is Resistant to Crizotinib.Detection of known and novel ALK fusion transcripts in lung cancer patients using next-generation sequencing approachesNext-Generation Sequencing and Immunohistochemistry as Future Gold Standard of ALK Testing in Lung Cancer?Simultaneous diagnostic platform of genotyping EGFR, KRAS, and ALK in 510 Korean patients with non-small-cell lung cancer highlights significantly higher ALK rearrangement rate in advanced stage.Discrepancies between FISH and immunohistochemistry for assessment of the ALK status are associated with ALK 'borderline'-positive rearrangements or a high copy number: a potential major issue for anti-ALK therapeutic strategies.Coexistent genetic alterations involving ALK, RET, ROS1 or MET in 15 cases of lung adenocarcinoma.Immunohistochemistry for predictive biomarkers in non-small cell lung cancer.Anaplastic Lymphoma Kinase Testing: IHC vs. FISH vs. NGS.The prevalence of ALK rearrangement in pulmonary adenocarcinomas in an unselected Caucasian population from a defined catchment area: impact of smoking.Comment on: "Non-Small-Cell Lung Cancer (NSCLC) Harboring ALK Translocations: Clinical Characteristics and Management in a Real-Life Setting: a French Retrospective Analysis (GFPC 02-14 Study)".Concomitant ALK translocation and EGFR mutation in lung cancer: a comparison of direct sequencing and sensitive assays and the impact on responsiveness to tyrosine kinase inhibitor.ALK protein expression in pulmonary adenocarcinoma of Tunisian patients.
P2860
Q26738387-B2C53B5A-EF79-462E-8123-5F02C9414828Q26738390-ABC89FE9-50D2-4B7D-B8EB-0C8489FD9914Q26740329-7CD5B40C-7C13-4D12-AA4C-4939D70086BCQ30234436-79AACE5E-BDA6-4620-8E1C-7C8CA9036233Q30240700-FFD52987-0088-4771-B345-B00B400938B7Q34231928-9ECB7E61-EF7C-4B11-819D-67A8480912E9Q34489837-ED8B5FC4-6CF7-428C-AAA6-DC27EAF9A514Q34564071-E94C4DD3-52FE-4F68-A666-D64DD77A06E8Q34662576-F1287FE0-1752-4DB3-BB71-594757BD6CD8Q35192525-4A2D7A0A-3868-41BC-B376-0B4A1AAFD302Q36096398-B5E9A7E9-BC91-4E39-B446-3F7C46F5731EQ36731901-4B5DAF9D-90DD-49C1-9962-EAD4F701F14BQ37108261-F9D8795A-6454-4C63-A632-E98B1DB6719FQ37392933-97493EF9-7646-4F81-AEA8-70EE2996EBEFQ37424085-23985313-97B8-496B-9A51-32CFD746C962Q37665697-D50C2E93-6B4A-489A-A950-B44C5DC0749EQ37696243-733855D6-B189-488D-ADC0-C7A0B7A49072Q38352879-90CEE53C-DDA4-476B-90BD-6E6E9CBAA9F5Q38567805-A8F2858C-7BB3-47F3-B6EF-52ADA28FCB5BQ38635259-93693EC5-F961-4C12-8FD7-B6594C6E0B1BQ38816700-BCB947C8-7B5B-458A-9837-68A7975A78A1Q38820412-7EF47A0C-12EA-4188-8185-D46DF06F929EQ39027394-383E1C70-9E2C-4394-AEA4-9E5E845C54B3Q39449763-62BEEA29-7512-4D9B-A5F5-864E93DB0D36Q40084048-7E027A26-A0C7-491A-BBA5-8BD9CFD97CE5Q40513502-2AFD78A9-0C0D-4F25-9B33-B2F3A7EC6DB4Q41162110-BB3EEF4B-C0A8-478B-8DE9-5F9CD4A86651Q41523237-E2468670-27A8-4FE4-8728-04D882D170D6Q41536166-03586620-E7F8-4BC6-A50A-62554D52B432Q42286165-28279D44-E84E-4A23-A6DF-0D88180A65D3Q42415357-626DB3B7-92F7-424A-BC22-6D7F0126A3A2Q43860596-AFDE8C7B-BF50-4538-BEC2-18AD859F7007Q43901317-6026DC69-F9B7-49D4-9959-9A56BABD1CD1Q46556584-2774FB6D-A3CA-43F2-A062-18FD5A4E0D14Q47140225-FCDF96A7-FD40-4936-AD6E-8034A5021A2DQ47578326-14B49E3A-9DA4-4C96-B79E-92504F8ECB03Q48021469-C459E501-C5ED-4F4B-AC71-C320A8E64760Q48108925-92F9DBED-434D-4F4E-A6E2-D59FFC60805CQ51034792-8A75C2F4-7A3D-492D-8E09-A22CF1C83850Q51049573-1039B40E-71BC-4B93-9774-75E511FAB96E
P2860
Parallel FISH and immunohistochemical studies of ALK status in 3244 non-small-cell lung cancers reveal major discordances.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh
2014年學術文章
@zh-hant
name
Parallel FISH and immunohistoc ...... ers reveal major discordances.
@en
Parallel FISH and immunohistoc ...... ers reveal major discordances.
@nl
type
label
Parallel FISH and immunohistoc ...... ers reveal major discordances.
@en
Parallel FISH and immunohistoc ...... ers reveal major discordances.
@nl
prefLabel
Parallel FISH and immunohistoc ...... ers reveal major discordances.
@en
Parallel FISH and immunohistoc ...... ers reveal major discordances.
@nl
P2093
P1476
Parallel FISH and immunohistoc ...... ers reveal major discordances.
@en
P2093
Alexandra Lespagnol
Audrey Gros
Dan Cristian Chiforeanu
Dominique Dachary
Florian Cabillic
Frédéric Dugay
Gwendoline Soler
Hugues Begueret
Jean-Philippe Merlio
Julien Dagher
P304
P356
10.1097/JTO.0000000000000072
P577
2014-03-01T00:00:00Z